Vericel (VCEL) Operating Leases (2019 - 2026)
Vericel (VCEL) posted Operating Leases of $93.1 million for Q2 2026, down 2.01% sequentially from $95.0 million in Q1 2026, and down 7.27% YoY from $100.4 million in Q2 2025.
Vericel (VCEL) Operating Leases (2019 - 2026) Analysis & Trends
Vericel has reported Operating Leases for 8 years, with the latest figure at $93.1 million in Q2 2026.
- Quarterly Operating Leases fell 7.27% year-over-year to $93.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $93.1 million (down 7.27% YoY) and the FY2025 annual result came in at $96.9 million, down 2.66% from the prior year.
- Operating Leases eased to $93.1 million in Q2 2026 per VCEL's latest filing, from $95.0 million in the prior quarter.
- Over five years, Operating Leases peaked at $100.4 million in Q2 2025 and troughed at $46.1 million in Q1 2022.
- A 5-year average of $81.2 million and a median of $92.6 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2024 and 2026: Operating Leases surged 96.56% in 2024, then decreased 7.27% in 2026.
- Over 5 years, Operating Leases stood at $47.6 million in 2022, then jumped by 84.92% to $88.0 million in 2023, then rose by 13.05% to $99.5 million in 2024, then declined by 2.66% to $96.9 million in 2025, then retreated by 3.88% to $93.1 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $93.1 million, $95.0 million, and $96.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 93.13 Mn |
| Mar 31, 2026 | 95.04 Mn |
| Dec 31, 2025 | 96.89 Mn |
| Sep 30, 2025 | 98.67 Mn |
| Jun 30, 2025 | 86.01 Mn |
| Mar 31, 2025 | 99.65 Mn |
| Dec 31, 2024 | 89.59 Mn |
| Sep 30, 2024 | 91.34 Mn |
| Jun 30, 2024 | 95.59 Mn |
| Mar 31, 2024 | 92.15 Mn |
| Dec 31, 2023 | 81.86 Mn |
| Sep 30, 2023 | 85.00 Mn |
| Jun 30, 2023 | 83.38 Mn |
| Mar 31, 2023 | 46.88 Mn |
| Dec 31, 2022 | 43.27 Mn |
| Sep 30, 2022 | 48.12 Mn |
| Jun 30, 2022 | 48.18 Mn |
| Mar 31, 2022 | 46.07 Mn |
| Dec 31, 2021 | 50.18 Mn |
| Sep 30, 2021 | 48.54 Mn |